多西环素与阿奇霉素治疗女性合并阴道感染的肛门直肠沙眼衣原体感染(CHLAZIDOXY研究):一项多中心、开放标签、随机、对照、优效性试验
在法国7个中心纳入460例沙眼衣原体阴道拭子阳性的成年女性,随机接受阿奇霉素单剂1g或多西环素100mg每日两次共7天。改良意向治疗人群中,多西环素组肛门直肠微生物学治愈率94%(147/156)高于阿奇霉素组85%(120/142),校正比值比0.43(95%CI 0.21-0.91;p=0.0274)。作者认为多西环素应作为女性沙眼衣原体感染的一线治疗。
要点
- 多西环素7天方案肛门直肠沙眼衣原体治愈率94%,高于阿奇霉素单剂1g的85%。
- 校正比值比0.43(95%CI 0.21-0.91;p=0.0274),支持多西环素优效。
- 治疗相关不良事件多西环素组11%(24/228) vs 阿奇霉素组13%(29/228)。
核心结论
- 接受阿奇霉素单剂1g的女性肛门直肠微生物学治愈率显著低于接受多西环素100mg每日两次共7天的女性。
- 作者认为该发现提示多西环素应作为女性沙眼衣原体感染的一线治疗。
研究设计与样本
- 多中心、开放标签、随机、对照、优效性试验,涉及法国4个性传播感染筛查中心和3个妊娠终止中心。
- 纳入性活跃成年女性(≥18岁),阴道拭子沙眼衣原体阳性并同意自采肛门直肠拭子检测。
- 按1:1随机分配,区组大小6和8,按各研究中心分层,阿奇霉素组230例、多西环素组230例。
- 主要结局为治疗开始后6周肛门直肠标本沙眼衣原体核酸扩增试验(NAAT)阴性的微生物学治愈率,在改良意向治疗人群中分析。
主要发现
- 2018年10月19日至2020年4月17日随机分配460例,多西环素组230例、阿奇霉素组230例。
- 456例中357例(78%)基线肛门直肠NAAT阳性,其中多西环素组184例(52%)、阿奇霉素组173例(48%),构成改良意向治疗人群。
- 多西环素组微生物学治愈147/156(94%,28例缺失值) vs 阿奇霉素组120/142(85%,31例缺失值),校正比值比0.43(95%CI 0.21-0.91;p=0.0274)。
- 可能与治疗相关的不良事件报告于456例中的53例(12%):多西环素组24/228(11%) vs 阿奇霉素组29/228(13%)。
- 胃肠道疾病最常见,456例中43例(9%):多西环素组17/228(8%) vs 阿奇霉素组26/228(11%)。
临床怎么用
- 作者认为多西环素应作为女性沙眼衣原体感染的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anorectal infections with Chlamydia trachomatis are commonly found in women. Although the efficacy of doxycycline and azithromycin is comparable in the treatment of urogenital infection, their efficacies toward anorectal infection remain unclear. We therefore aimed to compare a single dose of azithromycin with a 7-day course of doxycycline for the treatment of anorectal C trachomatis infection in women with concurrent vaginal infection. METHODS: We did a multicentre, open-label, randomised, controlled, superiority trial involving four sexually transmitted infection screening centres and three pregnancy termination centres in France. We included sexually active adult women (≥18 years) with a positive C trachomatis vaginal swab who agreed to provide self-collected anorectal swabs for C trachomatis detection. Participants were randomly assigned (1:1), using block sizes of six and eight and stratification by each investigating centre, to orally receive either azithromycin (a single 1-g dose, with or without food) or doxycycline (100 mg in the morning and evening at mealtimes for 7 days [ie, 100 mg of doxycycline twice per day for 7 days]). All laboratory staff who did the bacteriological analyses, but not the participants and the investigators, were masked to the treatment groups. The primary outcome was the microbiological anorectal cure rate defined as a C trachomatis-negative nucleic acid amplification test (NAAT) result in anorectal specimens 6 weeks after treatment initiation among women who had a baseline C trachomatis-positive anorectal NAAT result. The primary analysis was done in the modified intention-to-treat population, with multiple imputation, which included all women who underwent randomisation and had a C trachomatis-positive vaginal and anorectal NAAT result at baseline. Adverse events were reported in all women who underwent randomisation. This study is registered with ClinicalTrials.gov, number NCT03532464. FINDINGS: Between Oct 19, 2018, and April 17, 2020, we randomly assigned a total of 460 participants to either the doxycycline group (n=230) or the azithromycin group (n=230). Four (1%) of 460 participants were excluded because they refused to take doxycycline or were found to be ineligible after randomisation. Among the 456 participants, 357 (78%) had a concurrent C trachomatis-positive anorectal NAAT result at baseline; 184 (52%) of 357 were in the doxycycline group and 173 (48%) were in the azithromycin group (ie, the modified intention-to-treat population). Microbiological anorectal cure occurred in 147 (94%) of 156 participants in the doxycycline group (28 missing values) versus 120 (85%) of 142 in the azithromycin group (31 missing values; adjusted odds ratio with imputation of missing values 0·43 [95% CI 0·21-0·91]; p=0·0274). Reported adverse events possibly related to treatment were notified in 53 (12%) of 456 women: 24 (11%) of 228 in the doxycycline group and 29 (13%) of 228 in the azithromycin group. Gastrointestinal disorders were the most frequently occurring, in 43 (9%) of 456 women: 17 (8%) of 228 in the doxycycline group and 26 (11%) of 228 in the azithromycin group. INTERPRETATION: The microbiological anorectal cure rate was significantly lower among women who received a single dose of azithromycin than among those who received a 1-week course of doxycycline. This finding suggests that doxycycline should be the first-line therapy for C trachomatis infection in women. FUNDING: French Ministry of Health. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
引用
- Peuchant O, Lhomme E, Martinet P, et al. Doxycycline versus azithromycin for the treatment of anorectal Chlamydia trachomatis infection in women concurrent with vaginal infection (CHLAZIDOXY study): a multicentre, open-label, randomised, controlled, superiority trial. Lancet Infect Dis. 2022. PMID: 35550262. doi:10.1016/S1473-3099(22)00148-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。